Dorothy M. Adcock

Dorothy M. Adcock

Auto-generated profile, based on publicly available information

Dorothy M. Adcock

Colorado Coagulation, Laboratory Corporation of America® Holdings, Englewood, CO, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2018 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
RGRobert C. Gosselin
Robert C. Gosselin
DADorothy M. Adcock
Dorothy M. Adcock
SBShannon M. Bates
Shannon M. Bates
JDJonathan Douxfils
Jonathan Douxfils
Emmanuel J FavaloroEmmanuel J Favaloro
Emmanuel J Favaloro
SKSteve Kitchen
Steve Kitchen
This guidance document was prepared on behalf of the International Council for Standardization in Haematology (ICSH) for providing haemostasis-related guidance documents for clinical laboratories. This inaugural coagulation ICSH document was developed by an ad hoc committee, comprised of international clinical and laboratory direct acting oral anticoagulant (DOAC) experts. The committee developed consensus recommendations for laboratory measurement of DOACs (dabigatran, rivaroxaban, apixaban and edoxaban), which would be germane for laboratories assessing DOAC anticoagulation. This guidance document addresses all phases of laboratory DOAC measurements, including pre-analytical (e.g. preferred time sample collection, preferred sample type, sample stability), analytical (gold standard method, screening and quantifying methods) and post analytical (e.g. reporting units, quality assurance). The committee addressed the use and limitations of screening tests such as prothrombin time, activated partial thromboplastin time as well as viscoelastic measurements of clotting blood and point of care methods. Additionally, the committee provided recommendations for the proper validation or verification of performance of laboratory assays prior to implementation for clinical use, and external quality assurance to provide continuous assessment of testing and reporting method.

1 July 2015 in Thrombosis Research
Verified
Journal Article
Open access
DAD.M. Adcock
D.M. Adcock
RGR. Gosselin
R. Gosselin
Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have recently been introduced and may have advantages over vitamin K antagonists such as warfarin. This review describes briefly the clinical utility and mechanism of action of these agents. Detailed information is provided on effect of these agents on routine assays including the APTT and PT as well as their impact on specialty laboratory assays. Also included are the use of drug specific assays and a discussion of alternative methods to determine relative drug concentration, such as evaluating drug calibrators in APTT and PT assays and using heparin calibrated anti-Xa assays to measure direct Xa inhibitors.

16 June 2012 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
DFDorothy M. Adcock Funk
Dorothy M. Adcock Funk
GLGiuseppe Lippi
Giuseppe Lippi
Emmanuel J FavaloroEmmanuel J Favaloro
Emmanuel J Favaloro
Samples for hemostasis testing drawn into sodium citrate anticoagulant are vulnerable to the effects of preanalytical variables associated with sample processing, transportation, and storage. These variables include the temperature at which samples are transported and stored; the stability of the samples once processed; whether maintained at room temperature, refrigerated, or frozen; methods of centrifugation; as well as the potential impact of using an automated line. Acknowledgment of these variables, as well as understanding their potential impact on assay results, is imperative to the reporting of high quality and accurate results. This article discusses the preanalytical issues associated with sample processing, transportation, and storage and also presents the ideal conditions for sample handling.

27 September 2021 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
SKSteve Kitchen
Steve Kitchen
DADorothy M. Adcock
Dorothy M. Adcock
RDRay Dauer
Ray Dauer
AKAnn‐Helen Kristoffersen
Ann‐Helen Kristoffersen
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
SNSukesh Nair
Sukesh Nair
This guidance document has been prepared on behalf of the International Council for Standardization in Haematology (ICSH). The aim of the document is to provide guidance and recommendations for the processing of citrated blood samples for coagulation tests in clinical laboratories in all regions of the world. The following areas are included in this document: Sample transport including use of pneumatic tubes systems; clots in citrated samples; centrifugation; primary tube storage and stability; interfering substances including haemolysis, icterus and lipaemia; secondary aliquots—transport, storage and processing; preanalytical variables for platelet function testing. The following areas are excluded from this document, but are included in an associated ICSH document addressing collection of samples for coagulation tests in clinical laboratories; ordering tests; sample collection tube and anticoagulant; preparation of the patient; sample collection device; venous stasis before sample collection; order of draw when different sample types are collected; sample labelling; blood‐to‐anticoagulant ratio (tube filling); influence of haematocrit. The recommendations are based on published data in peer‐reviewed literature and expert opinion.

8 May 2019 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
RGRobert C. Gosselin
Robert C. Gosselin
DADorothy M. Adcock
Dorothy M. Adcock
JDJonathan Douxfils
Jonathan Douxfils
The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa inhibitors, have been approved, including rivaroxaban, apixaban, edoxaban and betrixaban. Our knowledge about the effect of DOACs on laboratory testing, as well as the use of the laboratory for measuring DOACs has been an evolving process. These drugs are not routinely monitored in the same fashion as coumadin, but there is an increasing demand on the laboratory to have the capacity to adequately assess DOAC anticoagulant effect (pharmacodynamics) or levels (pharmacokinetics) in either emergent or the routine situations. This manuscript provides an update on laboratory guidance and progress of methods for measuring DOACs.

1 January 2013 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
DADorothy M. Adcock
Dorothy M. Adcock
RGRobert Gosselin
Robert Gosselin
SKSteve Kitchen
Steve Kitchen
DDDenis M. Dwyre
Denis M. Dwyre
MDMd
Md
Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor. An inhibitor of thrombin has the potential to interfere with essentially all clot-based coagulation assays and select chromogenic assays, whereas the drug would not be expected to interfere in antigen-based assays. The purpose of this study was to evaluate the effect of dabigatran on various specialized coagulation assays using normal plasma specimens with varying concentrations of dabigatran (the active form of dabigatran etexilate). We have demonstrated that samples containing therapeutic levels of dabigatran may lead to underestimation of intrinsic factor activities with abnormal activated partial thromboplastin time (aPTT) mixing study results and a false-positive factor VIII Bethesda titer; overestimation of protein C and protein S activity and activated protein C resistance ratio when determined using aPTT-based methods; and overestimation of results based on chromogenic anti-IIa assays but no effect on antigen assays and select chromogenic assays.